Therapeutic Strategies for Resectable Stage-IIIA N2 Non-Small Cell Lung Cancer Patients: A Network Meta-Analysis.
Ziyang ShenYa LuYing SuiSitong FengJi-Feng FengJinrong ZhouPublished in: Clinical Medicine Insights. Oncology (2022)
Since lobectomy and pneumonectomy following neoadjuvant treatments had equivalent efficacy in prolonging OS for patients with stage-IIIA N2 NSCLC compared with definitive radiotherapy, young patients with favorable performance status (0) should try surgery to pursue better prognosis while elderly patients with unfavorable PS or radiosensitive pathology types should accept definitive radiotherapy. More high-quality clinical trials are needed to support our findings.
Keyphrases
- locally advanced
- rectal cancer
- squamous cell carcinoma
- clinical trial
- radiation therapy
- middle aged
- minimally invasive
- small cell lung cancer
- single cell
- coronary artery bypass
- cell therapy
- advanced non small cell lung cancer
- early stage
- randomized controlled trial
- surgical site infection
- stem cells
- community dwelling
- mesenchymal stem cells
- phase iii
- open label
- lymph node
- thoracic surgery
- tyrosine kinase